Zila, P&G deal

P&G gave 90-day notice of its intention to end its agreement to market OraScan, ZILA's oral cancer diagnostic, in the U.S. and 55 other countries (see BioCentury Feb. 5). According to ZILA, P&G is refocusing resources on its existing health care brands. ...